Clinical Trials Logo

Clinical Trial Summary

To compare the ocular tolerance, safety and ocular pharmacokinetics of 3 concentrations (0.5% - 1.0% - 1.5%) and the vehicle of T1225.


Clinical Trial Description

The present phase I clinical trial was performed in order to investigate the ocular tolerance, safety and the ocular pharmacokinetics of a single administration of T1225 eye drops (0.5%, 1.0%, or 1.5%) in healthy volunteers. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00357539
Study type Interventional
Source Laboratoires Thea
Contact
Status Completed
Phase Phase 1
Start date February 2002
Completion date March 2002

See also
  Status Clinical Trial Phase
Completed NCT00324168 - Steroids for Corneal Ulcers Trial Phase 4
Completed NCT00357383 - Study of the Ocular Safety After Repeated Instillations of T1225 1% or 1.5% Eye Drops in Healthy Volunteers Phase 1
Completed NCT00356850 - Ocular Pharmacokinetics After a Single Drop Instillation of T1225 0.5, 1, 1.5% in 91 Healthy Volunteers Phase 1
Completed NCT00357292 - Ocular Tolerance, Safety and Ocular Pharmacokinetics After 1 Drop of T1225 0.5, 1.0, 1.5% in 48 Healthy Volunteers Phase 1
Completed NCT00356772 - Azithromycin Level in Tears and in Conjunctiva in 36 Healthy Volunteers Phase 1
Recruiting NCT04981860 - Comparison of Conjunctival Antimicrobial Activity and Patient Comfort Between Topical Hypochlorous Acid (Avenova) and Betadine Phase 4